4:47 PM
 | 
Mar 01, 2019
 |  BC Extra  |  Company News

Emerging company roundup: Anthos, Maze, Oyster Point

In a week that had at least four companies post venture raises north of $80 million, Maze Therapeutics and Anthos Therapeutics Inc. had the biggest hauls, with financings near or above $200 million.

Blackstone partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. Baxalta Inc. and Novartis veteran John Glasspool will lead the newco as CEO; Nick Galakatos, head of Blackstone Life Sciences, is chairman. The deal was the first led by Blackstone since it acquired Clarus Ventures last fall (see “Blackstone, Novartis Spin Out...

Read the full 454 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >